2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

[1]  M. Link,et al.  Prediction and Prevention of Sudden Death in Young Patients (<20 years) With Hypertrophic Cardiomyopathy. , 2020, The American journal of cardiology.

[2]  B. Maron,et al.  Outcomes in Patients With Hypertrophic Cardiomyopathy and Left Ventricular Systolic Dysfunction. , 2020, Journal of the American College of Cardiology.

[3]  S. Solomon,et al.  Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. , 2020, Journal of the American College of Cardiology.

[4]  I. Olivotto,et al.  Study Design and Rationale of EXPLORER-HCM , 2020, Circulation. Heart failure.

[5]  C. Lavie,et al.  Significance of Pulmonary Hypertension in Hypertrophic Cardiomyopathy. , 2020, Current problems in cardiology.

[6]  S. Colan,et al.  A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy , 2020, Circulation.

[7]  E. Ashley,et al.  Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction , 2020, Circulation.

[8]  B. Maron,et al.  Distinctive Hypertrophic Cardiomyopathy Anatomy and Obstructive Physiology in Patients Admitted With Takotsubo Syndrome. , 2020, The American journal of cardiology.

[9]  Y. Shimada,et al.  Impact of Septal Myectomy Volume on Mitral-Valve Replacement Rate in Hypertrophic Cardiomyopathy Patients , 2020, Cardiology.

[10]  M. Landzberg,et al.  Planned vaginal delivery and cardiovascular morbidity in pregnant women with heart disease. , 2020, American journal of obstetrics and gynecology.

[11]  H. Rakowski,et al.  Hypertrophic Cardiomyopathy-Related Sudden Cardiac Death in Young People in Ontario. , 2019, Circulation.

[12]  Hai-Chao Han,et al.  Hemodynamic effects of myocardial bridging in patients with hypertrophic cardiomyopathy. , 2019, American journal of physiology. Heart and circulatory physiology.

[13]  N. Sreeram,et al.  Risk factors for lethal arrhythmic events in children and adolescents with hypertrophic cardiomyopathy and an implantable defibrillator: An international multicenter study. , 2019, Heart rhythm.

[14]  R. Weintraub,et al.  Development of a Novel Risk Prediction Model for Sudden Cardiac Death in Childhood Hypertrophic Cardiomyopathy (HCM Risk-Kids). , 2019, JAMA cardiology.

[15]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[16]  S. Ommen,et al.  Conduction Abnormalities and Long-Term Mortality Following Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy. , 2019, Journal of the American College of Cardiology.

[17]  B. Wessler,et al.  Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes. , 2019, Circulation. Cardiovascular interventions.

[18]  P. Neužil,et al.  Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. , 2019, Journal of the American College of Cardiology.

[19]  M. Link,et al.  Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy. , 2019, JAMA cardiology.

[20]  N. Sreeram,et al.  Impact of Obesity on Left Ventricular Thickness in Children with Hypertrophic Cardiomyopathy , 2019, Pediatric Cardiology.

[21]  M. Tanter,et al.  Myocardial Stiffness Evaluation Using Noninvasive Shear Wave Imaging in Healthy and Hypertrophic Cardiomyopathic Adults , 2019, JACC. Cardiovascular imaging.

[22]  M. Lafreniere-Roula,et al.  Family screening for hypertrophic cardiomyopathy: Is it time to change practice guidelines? , 2019, European heart journal.

[23]  D. Corrado,et al.  Structurally Normal Hearts Are Uncommonly Associated With Sudden Deaths in Athletes and Young People. , 2019, Journal of the American College of Cardiology.

[24]  R. Omar,et al.  A validation study of the European Society of Cardiology guidelines for risk stratification of sudden cardiac death in childhood hypertrophic cardiomyopathy , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[25]  M. Link,et al.  Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy. , 2019, The American journal of cardiology.

[26]  N. Smedira,et al.  Surgical management of left ventricular outflow tract obstruction in a specialized hypertrophic obstructive cardiomyopathy center. , 2019, The Journal of thoracic and cardiovascular surgery.

[27]  Matthew W. Martinez,et al.  Establishment of Specialized Clinical Cardiovascular Genetics Programs: Recognizing the Need and Meeting Standards: A Scientific Statement From the American Heart Association. , 2019, Circulation. Genomic and precision medicine.

[28]  L. Meng,et al.  Obstructive sleep apnea is associated with nonsustained ventricular tachycardia in patients with hypertrophic obstructive cardiomyopathy. , 2019, Heart rhythm.

[29]  A. Owens,et al.  Mavacamten Treatment for Obstructive Hypertrophic Cardiomyopathy , 2019, Annals of Internal Medicine.

[30]  Joshua L. Deignan,et al.  Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG) , 2019, Genetics in Medicine.

[31]  P. Elliott,et al.  Yield of Clinical Screening for Hypertrophic Cardiomyopathy in Child First-Degree Relatives , 2019, Circulation.

[32]  S. Ommen,et al.  Apical myectomy for patients with hypertrophic cardiomyopathy and advanced heart failure. , 2019, The Journal of thoracic and cardiovascular surgery.

[33]  J. Cigarroa,et al.  Recent Innovations, Modifications, and Evolution of ACC/AHA Clinical Practice Guidelines: An Update for Our Constituencies: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[34]  B. Maron,et al.  Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)". , 2019, Circulation.

[35]  Stefan L. Zimmerman,et al.  Hypertrophic Cardiomyopathy Patients With Paroxysmal Atrial Fibrillation Have a High Burden of Left Atrial Fibrosis by Cardiac Magnetic Resonance Imaging. , 2019, JACC. Clinical electrophysiology.

[36]  S. Ommen,et al.  Accuracy of Jet Direction on Doppler Echocardiography in Identifying the Etiology of Mitral Regurgitation in Obstructive Hypertrophic Cardiomyopathy , 2019, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[37]  S. Colan,et al.  Left Ventricular Strain Is Abnormal in Preclinical and Overt Hypertrophic Cardiomyopathy: Cardiac MR Feature Tracking. , 2019, Radiology.

[38]  B. Maron,et al.  Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy. , 2019, Circulation.

[39]  C. Caleshu,et al.  Evaluating the Clinical Validity of Hypertrophic Cardiomyopathy Genes , 2019, Circulation. Genomic and precision medicine.

[40]  B. Bateman.  What's New in Obstetric Anesthesia: a focus on maternal morbidity and mortality. , 2019, International journal of obstetric anesthesia.

[41]  H. Schaff,et al.  Surgical Myectomy: Subaortic, Midventricular, and Apical. , 2019, Cardiology clinics.

[42]  Hugh Calkins,et al.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Journal of the American College of Cardiology.

[43]  B. Maron,et al.  Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy. , 2019, JACC. Clinical electrophysiology.

[44]  S. Ommen,et al.  Septal Myectomy in Hypertrophic Cardiomyopathy: National Outcomes of Concomitant Mitral Surgery , 2019, Mayo Clinic proceedings.

[45]  Joshua L. Deignan,et al.  Patient re-contact after revision of genomic test results: points to consider—a statement of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[46]  H. Heidbuchel,et al.  Recommendations for participation in competitive and leisure time sport in athletes with cardiomyopathies, myocarditis, and pericarditis: position statement of the Sport Cardiology Section of the European Association of Preventive Cardiology (EAPC). , 2018, European heart journal.

[47]  H. Seggewiss,et al.  Survival After Alcohol Septal Ablation in Patients With Hypertrophic Obstructive Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[48]  C. Rusin,et al.  Early experience with intravenous sotalol in children with and without congenital heart disease. , 2018, Heart rhythm.

[49]  S. Chevret,et al.  CONGENITAL : CARDIOMYOPATHY Long-term results of the modified Konno procedure in high-risk children with obstructive hypertrophic cardiomyopathy G , 2022 .

[50]  G. Lip,et al.  Effectiveness and Safety of Non‐Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study , 2018, Chest.

[51]  S. Carlson,et al.  The Physical Activity Guidelines for Americans , 2018, JAMA.

[52]  E. Nicol,et al.  Heart muscle disease management in aircrew , 2018, Heart.

[53]  Y. Agmon,et al.  Multilayer Myocardial Mechanics in Genotype-Positive Left Ventricular Hypertrophy-Negative Patients With Hypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[54]  J. Burns,et al.  Disparities in the Diagnosis of Hypertrophic Obstructive Cardiomyopathy: A Narrative Review of Current Literature , 2018, Cardiology research and practice.

[55]  A. Tajik,et al.  Marked respiratory-related fluctuations in left ventricular outflow tract gradients in hypertrophic obstructive cardiomyopathy: an observational study , 2018, European heart journal cardiovascular Imaging.

[56]  Michael J Ackerman,et al.  2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2018, Journal of the American College of Cardiology.

[57]  B. Maron,et al.  Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[58]  C. Autore,et al.  Long-Term Left Ventricular Remodeling of Patients With Hypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[59]  K. Ball,et al.  A Control Theory-Based Pilot Intervention toIncrease Physical Activity in Patients WithHypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[60]  Susanna Price,et al.  2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. , 2018, European heart journal.

[61]  Amit R. Patel,et al.  Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy , 2018, Circulation.

[62]  B. Maron,et al.  Clinical Course and Management of Hypertrophic Cardiomyopathy , 2018, The New England journal of medicine.

[63]  S. Ommen,et al.  Determinants of Reverse Remodeling of the Left Atrium After Transaortic Myectomy. , 2018, The Annals of thoracic surgery.

[64]  N. Smedira,et al.  CONGENITAL : HYPERTROPHIC CARDIOMYOPATHY Prediction of sudden death risk in obstructive hypertrophic cardiomyopathy : Potential for refinement of current criteria , 2018 .

[65]  N. Smedira,et al.  Late Gadolinium Enhancement in Patients With Hypertrophic Cardiomyopathy and Preserved Systolic Function. , 2018, Journal of the American College of Cardiology.

[66]  R. Levine,et al.  Intrinsic mitral valve alterations in hypertrophic cardiomyopathy sarcomere mutation carriers , 2018, European heart journal cardiovascular Imaging.

[67]  Glyn Elwyn,et al.  Interventions for increasing the use of shared decision making by healthcare professionals. , 2018, The Cochrane database of systematic reviews.

[68]  B. Maron,et al.  Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy. , 2018, The American journal of medicine.

[69]  Marcel E Dinger,et al.  Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. , 2018, Journal of the American College of Cardiology.

[70]  F. Drago,et al.  Subcutaneous implantable cardioverter-defibrillator: is it ready for use in children and young adults? A single-centre study , 2018, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[71]  C. Rapezzi,et al.  Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events , 2018, JAMA cardiology.

[72]  B. Maron,et al.  Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy. , 2018, Circulation.

[73]  B. Gersh,et al.  Hypertrophic Cardiomyopathy: Clinical Update. , 2018, JACC. Heart failure.

[74]  Rajiv Mahajan,et al.  Subclinical device-detected atrial fibrillation and stroke risk: a systematic review and meta-analysis , 2018, European heart journal.

[75]  B. Maron,et al.  Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy. , 2018, The American journal of cardiology.

[76]  M. Chung,et al.  Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: A case series and literature review , 2018, Pacing and clinical electrophysiology : PACE.

[77]  R. Oldenburg,et al.  Outcomes of Contemporary Family Screening in Hypertrophic Cardiomyopathy , 2018, Circulation. Genomic and precision medicine.

[78]  Sainan Cheng,et al.  CMR assessment and clinical outcomes of hypertrophic cardiomyopathy with or without ventricular remodeling in the end-stage phase , 2018, The International Journal of Cardiovascular Imaging.

[79]  J. Minnier,et al.  Standardized Goal‐Directed Valsalva Maneuver for Assessment of Inducible Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[80]  M. Ackerman,et al.  Return-to-Play for Athletes With Genetic Heart Diseases. , 2018, Circulation.

[81]  S. Ommen,et al.  Does septal thickness influence outcome of myectomy for hypertrophic obstructive cardiomyopathy?† , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[82]  K. Aonuma,et al.  Radiofrequency Catheter Ablation of Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy and Apical Aneurysm. , 2018, JACC. Clinical electrophysiology.

[83]  O. Wever-Pinzon,et al.  Outcomes in Patients With Hypertrophic Cardiomyopathy Awaiting Heart Transplantation , 2018, Circulation. Heart failure.

[84]  S. Ommen,et al.  Predictors of Exercise Capacity in Patients with Hypertrophic Obstructive Cardiomyopathy , 2018, Journal of clinical medicine.

[85]  M. Sherrid,et al.  Intraoperative Two‐ and Three‐Dimensional Transesophageal Echocardiography in Combined Myectomy‐Mitral Operations for Hypertrophic Cardiomyopathy , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[86]  Harald Becher,et al.  Clinical Applications of Ultrasonic Enhancing Agents in Echocardiography: 2018 American Society of Echocardiography Guidelines Update. , 2018, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[87]  M. Maurer,et al.  Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy , 2018, Circulation. Heart failure.

[88]  M. Lafreniere-Roula,et al.  Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy , 2018, Clinical genetics.

[89]  F. Hang,et al.  Clinical Outcomes of Myocardial Bridging versus No Myocardial Bridging in Patients with Apical Hypertrophic Cardiomyopathy , 2018, Cardiology.

[90]  S. Day,et al.  Exercise and Hypertrophic Cardiomyopathy: Time for a Change of Heart. , 2018, Circulation.

[91]  I. Olivotto,et al.  Cardiac Resynchronization Therapy for End-Stage Hypertrophic Cardiomyopathy: The Need for Disease-Specific Criteria. , 2018, Journal of the American College of Cardiology.

[92]  S. Caselli,et al.  Does Sport Participation Worsen the Clinical Course of Hypertrophic Cardiomyopathy? Clinical Outcome of Hypertrophic Cardiomyopathy in Athletes. , 2018, Circulation.

[93]  Birgit Funke,et al.  Adaptation and validation of the ACMG/AMP variant classification framework for MYH7-associated inherited cardiomyopathies: recommendations by ClinGen’s Inherited Cardiomyopathy Expert Panel , 2018, Genetics in Medicine.

[94]  S. Bowdin,et al.  Clinical genetic testing in pediatric cardiomyopathy: Is bigger better? , 2018, Clinical genetics.

[95]  L. Eckardt,et al.  Long-Term Experience With the Subcutaneous Implantable Cardioverter-Defibrillator in Teenagers and Young Adults. , 2017, JACC. Clinical electrophysiology.

[96]  M. Link,et al.  Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy , 2017, Circulation.

[97]  P. Pellikka,et al.  Comparison of Valsalva Maneuver, Amyl Nitrite, and Exercise Echocardiography to Demonstrate Latent Left Ventricular Outflow Obstruction in Hypertrophic Cardiomyopathy. , 2017, The American journal of cardiology.

[98]  Matthew W. Martinez,et al.  Exercise participation and shared decision-making in patients with inherited channelopathies and cardiomyopathies. , 2017, Heart rhythm.

[99]  Snehal R. Patel,et al.  Outcomes of Restrictive and Hypertrophic Cardiomyopathies After LVAD: An INTERMACS Analysis. , 2017, Journal of cardiac failure.

[100]  J. Menteer,et al.  Outcomes of Berlin Heart EXCOR® pediatric ventricular assist device support in patients with restrictive and hypertrophic cardiomyopathy , 2017, Pediatric transplantation.

[101]  F. Domínguez,et al.  Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation. , 2017, International journal of cardiology.

[102]  H. Schaff,et al.  Electrical storms in patients with apical aneurysms and hypertrophic cardiomyopathy with midventricular obstruction: A case series , 2017, The Journal of thoracic and cardiovascular surgery.

[103]  A. Keren,et al.  International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM) , 2017, Circulation.

[104]  E. Topol,et al.  Molecular Autopsy for Sudden Death in the Young: Is Data Aggregation the Key? , 2017, Front. Cardiovasc. Med..

[105]  M. Hostiuc,et al.  Cardiovascular consequences of myocardial bridging: A meta-analysis and meta-regression , 2017, Scientific Reports.

[106]  J. Healey,et al.  Implantable cardioverter-defibrillator therapy in hypertrophic cardiomyopathy: A SIMPLE substudy. , 2017, Heart rhythm.

[107]  A. Go,et al.  Comparison of Inappropriate Shocks and Other Health Outcomes Between Single‐ and Dual‐Chamber Implantable Cardioverter‐Defibrillators for Primary Prevention of Sudden Cardiac Death: Results From the Cardiovascular Research Network Longitudinal Study of Implantable Cardioverter‐Defibrillators , 2017, Journal of the American Heart Association.

[108]  S. Ommen,et al.  Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy , 2017, The Journal of thoracic and cardiovascular surgery.

[109]  A. Uy‐Evanado,et al.  Population Burden of Sudden Death Associated With Hypertrophic Cardiomyopathy. , 2017, Circulation.

[110]  M. Ackerman,et al.  Competitive Sport Participation Among Athletes With Heart Disease: A Call for a Paradigm Shift in Decision Making. , 2017, Circulation.

[111]  B. Funke,et al.  Pathogenicity of Hypertrophic Cardiomyopathy Variants: A Path Forward Together. , 2017, Circulation. Cardiovascular genetics.

[112]  E. Daoud,et al.  Role of exercise electrocardiogram to screen for T-wave oversensing after implantation of subcutaneous implantable cardioverter-defibrillator. , 2017, Heart rhythm.

[113]  C. Autore,et al.  Long-term outcome of nonobstructive versus obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis. , 2017, International journal of cardiology.

[114]  E. Braunwald,et al.  Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.

[115]  R. Hall,et al.  Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC) , 2017, European heart journal.

[116]  L. Fauchier,et al.  Dual- vs. single-chamber defibrillators for primary prevention of sudden cardiac death: long-term follow-up of the Défibrillateur Automatique Implantable—Prévention Primaire registry , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[117]  G. Lip,et al.  Device-detected subclinical atrial tachyarrhythmias: definition, implications and management-an European Heart Rhythm Association (EHRA) consensus document, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulación Cardíaca y Elect , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[118]  A. Wilde,et al.  Penetrance of Hypertrophic Cardiomyopathy in Children Who Are Mutation Positive , 2017, The Journal of pediatrics.

[119]  A. Bogachev-Prokophiev,et al.  Concomitant ablation for atrial fibrillation during septal myectomy in patients with hypertrophic obstructive cardiomyopathy , 2017, Journal of Cardiothoracic Surgery.

[120]  M. Link,et al.  2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2017, Journal of the American College of Cardiology.

[121]  R. Chan,et al.  Discrepant Measurements of Maximal Left Ventricular Wall Thickness Between Cardiac Magnetic Resonance Imaging and Echocardiography in Patients With Hypertrophic Cardiomyopathy , 2017, Circulation. Cardiovascular imaging.

[122]  Jeroen J. Bax,et al.  Standards defining a 'Heart Valve Centre': ESC Working Group on Valvular Heart Disease and European Association for Cardiothoracic Surgery Viewpoint. , 2017, European heart journal.

[123]  D. Corrado,et al.  Accuracy of the ECG for differential diagnosis between hypertrophic cardiomyopathy and athlete’s heart: comparison between the European Society of Cardiology (2010) and International (2017) criteria , 2017, British Journal of Sports Medicine.

[124]  B. Maron,et al.  Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience. , 2017, Annals of cardiothoracic surgery.

[125]  B. Maron,et al.  How to Image Hypertrophic Cardiomyopathy. , 2017, Circulation. Cardiovascular imaging.

[126]  L. Fleisher,et al.  2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2017, Journal of the American College of Cardiology.

[127]  M. Link,et al.  Occurrence and Natural History of Clinically Silent Episodes of Atrial Fibrillation in Hypertrophic Cardiomyopathy. , 2017, American Journal of Cardiology.

[128]  O. Alfieri,et al.  Mid-term outcomes of concomitant surgical ablation of atrial fibrillation in patients undergoing cardiac surgery for hypertrophic cardiomyopathy† , 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[129]  R. Chan,et al.  Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients , 2017, Journal of the American Heart Association.

[130]  P. Elliott,et al.  Risk factors for sudden cardiac death in childhood hypertrophic cardiomyopathy: A systematic review and meta-analysis , 2017, European journal of preventive cardiology.

[131]  A. Capucci,et al.  Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT , 2017, European heart journal.

[132]  Akshay S. Desai,et al.  The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial , 2017, American heart journal.

[133]  M. Link,et al.  Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications , 2017, Journal of cardiovascular electrophysiology.

[134]  E. Ashley,et al.  Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial , 2017, JAMA.

[135]  T. Driscoll,et al.  Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications. , 2017, Circulation. Cardiovascular genetics.

[136]  Pier D Lambiase,et al.  Disease Severity and Exercise Testing Reduce Subcutaneous Implantable Cardioverter-Defibrillator Left Sternal ECG Screening Success in Hypertrophic Cardiomyopathy , 2017, Circulation. Arrhythmia and electrophysiology.

[137]  Theodore P Abraham,et al.  The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study , 2017, JAMA cardiology.

[138]  W. Hua,et al.  Clinical outcome of cardiac resynchronization therapy in dilated-phase hypertrophic cardiomyopathy , 2017, Journal of geriatric cardiology : JGC.

[139]  M. Link,et al.  Prognostic Implications of Nonsustained Ventricular Tachycardia in High-Risk Patients With Hypertrophic Cardiomyopathy , 2017, Circulation. Arrhythmia and electrophysiology.

[140]  M. Link,et al.  Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management. , 2017, Journal of the American College of Cardiology.

[141]  S. Ommen,et al.  Comparison of Maximal Wall Thickness in Hypertrophic Cardiomyopathy Differs Between Magnetic Resonance Imaging and Transthoracic Echocardiography. , 2017, The American journal of cardiology.

[142]  B. Maron,et al.  Shared decision-making in HCM , 2017, Nature Reviews Cardiology.

[143]  M. Komajda,et al.  Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. , 2017, Archives of cardiovascular diseases.

[144]  B. Maron,et al.  Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy. , 2017, The American journal of cardiology.

[145]  C. Autore,et al.  Prognostic Implications of Defibrillation Threshold Testing in Patients With Hypertrophic Cardiomyopathy , 2017, Journal of cardiovascular electrophysiology.

[146]  Stuart A. Cook,et al.  Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy. , 2016, Journal of the American College of Cardiology.

[147]  R. Chan,et al.  Prognostic Value of LGE-CMR in HCM: A Meta-Analysis. , 2016, JACC. Cardiovascular imaging.

[148]  B. Maron,et al.  Demographics and Epidemiology of Sudden Deaths in Young Competitive Athletes: From the United States National Registry. , 2016, The American journal of medicine.

[149]  Steven Swiryn,et al.  Clinical Implications of Brief Device-Detected Atrial Tachyarrhythmias in a Cardiac Rhythm Management Device Population: Results from the Registry of Atrial Tachycardia and Atrial Fibrillation Episodes , 2016, Circulation.

[150]  R. Chan,et al.  Usefulness of 14-Day Holter for Detection of Nonsustained Ventricular Tachycardia in Patients With Hypertrophic Cardiomyopathy. , 2016, The American journal of cardiology.

[151]  E. Topol,et al.  Molecular Autopsy for Sudden Unexpected Death. , 2016, JAMA.

[152]  A. Hughes,et al.  Mechanisms of Myocardial Ischemia in Hypertrophic Cardiomyopathy , 2016, Journal of the American College of Cardiology.

[153]  S. Ommen,et al.  Mitral Regurgitation in Patients With Hypertrophic Obstructive Cardiomyopathy: Implications for Concomitant Valve Procedures. , 2016, Journal of the American College of Cardiology.

[154]  E. Ashley,et al.  Interdisciplinary psychosocial care for families with inherited cardiovascular diseases. , 2016, Trends in cardiovascular medicine.

[155]  C. Autore,et al.  Heart Failure Progression in Hypertrophic Cardiomyopathy　- Possible Insights From Cardiopulmonary Exercise Testing. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[156]  T. Aiba,et al.  Single-Coil Defibrillator Leads Yield Satisfactory Defibrillation Safety Margin in Hypertrophic Cardiomyopathy. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[157]  E. Blackstone,et al.  Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease? , 2016, JACC. Heart failure.

[158]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[159]  Peter Szolovits,et al.  Genetic Misdiagnoses and the Potential for Health Disparities. , 2016, The New England journal of medicine.

[160]  A. Timperio,et al.  Physical activity in hypertrophic cardiomyopathy: prevalence of inactivity and perceived barriers , 2016, Open Heart.

[161]  Jeffrey S. Raskin,et al.  Minimally invasive posterior extrapleural thoracic sympathectomy in children with medically refractory arrhythmias. , 2016, Heart rhythm.

[162]  C. Glover,et al.  A meta analysis of current status of alcohol septal ablation and surgical myectomy for obstructive hypertrophic cardiomyopathy , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[163]  F. Marchlinski,et al.  Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials. , 2016, Heart rhythm.

[164]  S. Willems,et al.  High Incidence of De Novo and Subclinical Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy and Cardiac Rhythm Management Device , 2016, Journal of cardiovascular electrophysiology.

[165]  P. Noseworthy,et al.  Stroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation. , 2016, Journal of the American College of Cardiology.

[166]  Nicole M. Johnson,et al.  Clinical Genetic Testing for the Cardiomyopathies and Arrhythmias: A Systematic Framework for Establishing Clinical Validity and Addressing Genotypic and Phenotypic Heterogeneity , 2016, Front. Cardiovasc. Med..

[167]  J. Skinner,et al.  A Prospective Study of Sudden Cardiac Death among Children and Young Adults. , 2016, The New England journal of medicine.

[168]  H. Smeets,et al.  Hypertrophic remodelling in cardiac regulatory myosin light chain (MYL2) founder mutation carriers. , 2016, European heart journal.

[169]  R. Swaminathan,et al.  Hospital Volume Outcomes After Septal Myectomy and Alcohol Septal Ablation for Treatment of Obstructive Hypertrophic Cardiomyopathy: US Nationwide Inpatient Database, 2003-2011. , 2016, JAMA cardiology.

[170]  B. Gersh,et al.  Pulmonary hypertension is associated with worse survival in hypertrophic cardiomyopathy. , 2016, European heart journal cardiovascular Imaging.

[171]  P. Lambiase,et al.  Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis , 2016, Heart.

[172]  M. Maron,et al.  Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. , 2016, The American journal of cardiology.

[173]  E. Ashley,et al.  Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy , 2016, Echocardiography.

[174]  P. Lambiase,et al.  Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts. , 2016, Heart rhythm.

[175]  E. Ashley,et al.  Hypertrophic Cardiomyopathy as a Cause of Sudden Cardiac Death in the Young: A Meta-Analysis. , 2016, The American journal of medicine.

[176]  L. Axel,et al.  The Mitral Valve in Obstructive Hypertrophic Cardiomyopathy: A Test in Context. , 2016, Journal of the American College of Cardiology.

[177]  B. Gersh,et al.  Hemodynamic changes in systolic and diastolic function during isoproterenol challenge predicts symptomatic response to myectomy in hypertrophic cardiomyopathy with labile obstruction , 2016, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[178]  B. Maron,et al.  How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice. , 2016, JAMA cardiology.

[179]  Yi Shen,et al.  Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[180]  B. Gersh,et al.  The Natural History of Nonobstructive Hypertrophic Cardiomyopathy. , 2016, Mayo Clinic proceedings.

[181]  Stefan L. Zimmerman,et al.  Left ventricular wall thickness in patients with hypertrophic cardiomyopathy: a comparison between cardiac magnetic resonance imaging and echocardiography , 2016, The International Journal of Cardiovascular Imaging.

[182]  Jonathan Weinstock,et al.  Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience , 2016, Journal of the American Heart Association.

[183]  I. Moussa,et al.  Usefulness of Von Willebrand Factor Activity Indexes to Predict Therapeutic Response in Hypertrophic Cardiomyopathy. , 2016, The American journal of cardiology.

[184]  Zuo-ying Hu,et al.  Efficiencies and Complications of Dual Chamber versus Single Chamber Implantable Cardioverter Defibrillators in Secondary Sudden Cardiac Death Prevention: A Meta-analysis. , 2016, Heart, lung & circulation.

[185]  B. Maron,et al.  Hypertrophic Cardiomyopathy in Children, Adolescents, and Young Adults Associated With Low Cardiovascular Mortality With Contemporary Management Strategies , 2016, Circulation.

[186]  J. Petryka,et al.  Predictors of Long-Term Outcome in Children with Hypertrophic Cardiomyopathy , 2015, Pediatric Cardiology.

[187]  S. Ommen,et al.  Postprandial Hemodynamics in Hypertrophic Cardiomyopathy , 2015, Echocardiography.

[188]  B. Maron.  Historical Perspectives on Sudden Deaths in Young Athletes With Evolution over 35 Years. , 2015, The American journal of cardiology.

[189]  P. Elliott,et al.  Cardiopulmonary Exercise Testing and Prognosis in Hypertrophic Cardiomyopathy , 2015, Circulation. Heart failure.

[190]  B. Mahmoodi,et al.  A Systematic Review and Meta-Analysis of Long-Term Outcomes After Septal Reduction Therapy in Patients With Hypertrophic Cardiomyopathy. , 2015, JACC. Heart failure.

[191]  Laura A. Hatfield,et al.  Transvenous Implantable Cardioverter‐Defibrillator (ICD) Lead Performance: A Meta‐Analysis of Observational Studies , 2015, Journal of the American Heart Association.

[192]  M. Senni,et al.  Transaortic Chordal Cutting: Mitral Valve Repair for Obstructive Hypertrophic Cardiomyopathy With Mild Septal Hypertrophy. , 2015, Journal of the American College of Cardiology.

[193]  H. Bundgaard,et al.  Risk of Cardiomyopathy in Younger Persons With a Family History of Death from Cardiomyopathy: A Nationwide Family Study in a Cohort of 3.9 Million Persons , 2015, Circulation.

[194]  N. Smedira,et al.  Low Operative Mortality Achieved With Surgical Septal Myectomy: Role of Dedicated Hypertrophic Cardiomyopathy Centers in the Management of Dynamic Subaortic Obstruction. , 2015, Journal of the American College of Cardiology.

[195]  J. Hung,et al.  Mitral valve and papillary muscle abnormalities in hypertrophic obstructive cardiomyopathy , 2015, Current opinion in cardiology.

[196]  Y. Gerber,et al.  Role of ventricular assist therapy for patients with heart failure and restrictive physiology: Improving outcomes for a lethal disease. , 2015, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[197]  L. Benson,et al.  Distribution of Hypertrophy and Late Gadolinium Enhancement in Children and Adolescents with Hypertrophic Cardiomyopathy. , 2015, Congenital heart disease.

[198]  R. Omar,et al.  Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk‐CVA) , 2015, European journal of heart failure.

[199]  M. Ackerman,et al.  Original Research Put Into Perspective for the Practicing Clinician Incidence, Cause, and Comparative Frequency of Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A Decade in Review , 2015 .

[200]  N. Smedira,et al.  Left Ventricular Outflow Tract Obstruction in Hypertrophic Cardiomyopathy Patients Without Severe Septal Hypertrophy: Implications of Mitral Valve and Papillary Muscle Abnormalities Assessed Using Cardiac Magnetic Resonance and Echocardiography. , 2015, Circulation. Cardiovascular imaging.

[201]  N. Smedira,et al.  Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. , 2015, Heart rhythm.

[202]  S. Nagueh,et al.  Role of Imaging in the Evaluation of Patients at Risk for Sudden Cardiac Death: Genotype-Phenotype Intersection. , 2015, JACC. Cardiovascular imaging.

[203]  S. Neubauer,et al.  Exacerbation of cardiac energetic impairment during exercise in hypertrophic cardiomyopathy: a potential mechanism for diastolic dysfunction. , 2015, European heart journal.

[204]  J. Carlin,et al.  Sudden death in childhood cardiomyopathy: results from a long-term national population-based study. , 2015, Journal of the American College of Cardiology.

[205]  A. Tajik,et al.  Decreased exercise capacity and sleep-disordered breathing in patients with hypertrophic cardiomyopathy. , 2015, Chest.

[206]  A. Wilde,et al.  Sudden cardiac death in the young: the molecular autopsy and a practical approach to surviving relatives. , 2015, European heart journal.

[207]  M. Link,et al.  Hypertrophic Cardiomyopathy in Adulthood Associated With Low Cardiovascular Mortality With Contemporary Management Strategies. , 2015, Journal of the American College of Cardiology.

[208]  K. Doi,et al.  Excess anterior mitral leaflet in a patient with hypertrophic obstructive cardiomyopathy and systolic anterior motion. , 2015, Circulation.

[209]  Barry J Maron,et al.  New perspectives on the prevalence of hypertrophic cardiomyopathy. , 2015, Journal of the American College of Cardiology.

[210]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[211]  F. T. ten Cate,et al.  Long-term benefit of myectomy and anterior mitral leaflet extension in obstructive hypertrophic cardiomyopathy. , 2015, The American journal of cardiology.

[212]  I. Moussa,et al.  Remission of recurrent gastrointestinal bleeding after septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy‐associated acquired von Willebrand syndrome , 2015, Journal of thrombosis and haemostasis : JTH.

[213]  E. Antman,et al.  Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. , 2015, JACC. Heart failure.

[214]  O. Havndrup,et al.  Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. , 2015, The lancet. Diabetes & endocrinology.

[215]  Matthew S. Lebo,et al.  Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.

[216]  D. Babuty,et al.  Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study. , 2014, JACC. Heart failure.

[217]  D. Bluemke,et al.  Prediction of Sarcomere Mutations in Subclinical Hypertrophic Cardiomyopathy , 2014, Circulation. Cardiovascular imaging.

[218]  C. Grines,et al.  Results of ventricular septal myectomy and hypertrophic cardiomyopathy (from Nationwide Inpatient Sample [1998-2010]). , 2014, The American journal of cardiology.

[219]  Donna K Arnett,et al.  AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U.S. Department of Health and Human Services. , 2014, Journal of the American College of Cardiology.

[220]  F. Rutten,et al.  2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). , 2014, European heart journal.

[221]  K. Kario,et al.  Clinical significance of left ventricular apical aneurysms in hypertrophic cardiomyopathy patients: the role of diagnostic electrocardiography. , 2014, Journal of cardiology.

[222]  G. Feuchtner,et al.  Quantification of myocardial delayed enhancement and wall thickness in hypertrophic cardiomyopathy: multidetector computed tomography versus magnetic resonance imaging. , 2014, European journal of radiology.

[223]  W. Roberts,et al.  Advanced Heart Failure With Preserved Systolic Function in Nonobstructive Hypertrophic Cardiomyopathy: Under-Recognized Subset of Candidates for Heart Transplant , 2014, Circulation. Heart failure.

[224]  S. Ommen,et al.  Residual and recurrent gradients after septal myectomy for hypertrophic cardiomyopathy-mechanisms of obstruction and outcomes of reoperation. , 2014, The Journal of thoracic and cardiovascular surgery.

[225]  Giuseppe Limongelli,et al.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). , 2014, European heart journal.

[226]  B. Gersh,et al.  Surgical myectomy improves pulmonary hypertension in obstructive hypertrophic cardiomyopathy. , 2014, European heart journal.

[227]  E. Cook,et al.  Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy , 2014, Circulation.

[228]  Barry J Maron,et al.  Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. , 2014, Journal of the American College of Cardiology.

[229]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[230]  B. Gersh,et al.  Atrial Fibrillation in Hypertrophic Cardiomyopathy: Prevalence, Clinical Correlations, and Mortality in a Large High‐Risk Population , 2014, Journal of the American Heart Association.

[231]  J. Kobashigawa,et al.  Long-term outcomes of orthotopic heart transplantation for hypertrophic cardiomyopathy. , 2014, Transplantation proceedings.

[232]  Weili Zhang,et al.  Myocardial Bridging as a Common Phenotype of Hypertrophic Cardiomyopathy Has No Effect on Prognosis , 2014, The American journal of the medical sciences.

[233]  P. Agarwal,et al.  Clinical significance of late gadolinium enhancement in patients<20 years of age with hypertrophic cardiomyopathy. , 2014, The American journal of cardiology.

[234]  M. Ackerman,et al.  Pathogeneses of Sudden Cardiac Death in National Collegiate Athletic Association Athletes , 2014, Circulation. Arrhythmia and electrophysiology.

[235]  P. Lambiase,et al.  Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD Registry , 2014, European heart journal.

[236]  P. Lambiase,et al.  Heart Rate Recovery in Patients With Hypertrophic Cardiomyopathy , 2014, The American journal of cardiology.

[237]  W. Burchert,et al.  Hypertrophic cardiomyopathy in cardiac CT: a validation study on the detection of intramyocardial fibrosis in consecutive patients , 2014, The International Journal of Cardiovascular Imaging.

[238]  S. Colan,et al.  Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry , 2013, The Lancet.

[239]  A. McLean,et al.  Clinical Experience of Subcutaneous and Transvenous Implantable Cardioverter Defibrillators in Children and Teenagers , 2013, Pacing and clinical electrophysiology : PACE.

[240]  R. Frye,et al.  Assessment of coronary artery disease risk in 5463 patients undergoing cardiac surgery: when is preoperative coronary angiography necessary? , 2013, The Journal of thoracic and cardiovascular surgery.

[241]  L. Ferrucci,et al.  Comparison of clinical presentation, left ventricular morphology, hemodynamics, and exercise tolerance in obese versus nonobese patients with hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.

[242]  C. Semsarian,et al.  Determining pathogenicity of genetic variants in hypertrophic cardiomyopathy: importance of periodic reassessment , 2013, Genetics in Medicine.

[243]  Dhanunjaya R. Lakkireddy,et al.  Catheter Ablation of Atrial Fibrillation in Hypertrophic Cardiomyopathy: Long-Term Outcomes and Mechanisms of Arrhythmia Recurrence , 2013, Circulation. Arrhythmia and electrophysiology.

[244]  P. Elliott,et al.  Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review , 2013, Heart.

[245]  L. Jordaens,et al.  Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications. , 2013, American heart journal.

[246]  Yan Chaowu,et al.  Cardiovascular Magnetic Resonance Characteristics in Children With Hypertrophic Cardiomyopathy , 2013, Circulation. Heart failure.

[247]  V. Korley,et al.  Mexiletine as an Adjunctive Therapy to Amiodarone Reduces the Frequency of Ventricular Tachyarrhythmia Events in Patients With an Implantable Defibrillator , 2013, Journal of cardiovascular pharmacology.

[248]  S. Ommen,et al.  Transapical approach to myectomy for midventricular obstruction in hypertrophic cardiomyopathy. , 2013, The Annals of thoracic surgery.

[249]  W. Manning,et al.  Obesity and its association to phenotype and clinical course in hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[250]  S. El-Saiedi,et al.  Hypertrophic cardiomyopathy: prognostic factors and survival analysis in 128 Egyptian patients , 2013, Cardiology in the Young.

[251]  N. Smedira,et al.  Predictors of Long-Term Outcomes in Symptomatic Hypertrophic Obstructive Cardiomyopathy Patients Undergoing Surgical Relief of Left Ventricular Outflow Tract Obstruction , 2013, Circulation.

[252]  M. Sherrid,et al.  Treatment of Obstructive Hypertrophic Cardiomyopathy Symptoms and Gradient Resistant to First-Line Therapy With &bgr;-Blockade or Verapamil , 2013, Circulation. Heart failure.

[253]  M. Sherrid,et al.  Post-prandial upright exercise echocardiography in hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[254]  B. Maron,et al.  Papillary muscle insertion directly into the anterior mitral leaflet in hypertrophic cardiomyopathy, its identification and cause of outflow obstruction by cardiac magnetic resonance imaging, and its surgical management. , 2013, The American journal of cardiology.

[255]  F. Masoudi,et al.  Implantable cardioverter-defibrillator shocks: epidemiology, outcomes, and therapeutic approaches. , 2013, JAMA internal medicine.

[256]  M. Link,et al.  Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Long-Term Results of a Prospective Multinational Registry. , 2013, Circulation.

[257]  M. Link,et al.  Safety of Sports for Athletes With Implantable Cardioverter-Defibrillators: Results of a Prospective, Multinational Registry , 2013, Circulation.

[258]  J. Atherton,et al.  Clinical predictors of genetic testing outcomes in hypertrophic cardiomyopathy , 2013, Genetics in Medicine.

[259]  M. Link,et al.  Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. , 2013, Journal of the American College of Cardiology.

[260]  E. Argulian,et al.  Antihypertensive therapy in hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.

[261]  E. Ashley,et al.  Physical activity and other health behaviors in adults with hypertrophic cardiomyopathy. , 2013, The American journal of cardiology.

[262]  C. Henrikson,et al.  Implanted Defibrillators in Young Hypertrophic Cardiomyopathy Patients: A Multicenter Study , 2013, Pediatric Cardiology.

[263]  M. Robson,et al.  Blunted Myocardial Oxygenation Response During Vasodilator Stress in Patients With Hypertrophic Cardiomyopathy , 2013, Journal of the American College of Cardiology.

[264]  S. Ommen,et al.  Evaluation of apical pouches in hypertrophic cardiomyopathy using cardiac MRI , 2013, The International Journal of Cardiovascular Imaging.

[265]  Luca Segreti,et al.  Superior vena cava defibrillator coils make transvenous lead extraction more challenging and riskier. , 2013, Journal of the American College of Cardiology.

[266]  Daniel E. Singer,et al.  Device-detected atrial fibrillation and risk for stroke: an analysis of >10 000 patients from the SOS AF project (Stroke preventiOn Strategies based on Atrial Fibrillation information from implanted devices) , 2013, European heart journal.

[267]  Stefan L. Zimmerman,et al.  Relationship of Delayed Enhancement by Magnetic Resonance to Myocardial Perfusion by Positron Emission Tomography in Hypertrophic Cardiomyopathy , 2013, Circulation. Cardiovascular imaging.

[268]  K. Muthiah,et al.  Centrifugal Continuous-Flow Left Ventricular Assist Device in Patients With Hypertrophic Cardiomyopathy: A Case Series , 2013, ASAIO journal.

[269]  W. Manning,et al.  Risk Stratification and Outcome of Patients With Hypertrophic Cardiomyopathy ≥60 Years of Age , 2013, Circulation.

[270]  K. Siminovitch,et al.  Toronto Hypertrophic Cardiomyopathy Genotype Score for Prediction of a Positive Genotype in Hypertrophic Cardiomyopathy , 2013, Circulation. Cardiovascular genetics.

[271]  P. Lambiase,et al.  A validation study of the 2003 American College of Cardiology/European Society of Cardiology and 2011 American College of Cardiology Foundation/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy , 2013, Heart.

[272]  L. Køber,et al.  Penetrance of Hypertrophic Cardiomyopathy in Children and Adolescents: A 12-Year Follow-up Study of Clinical Screening and Predictive Genetic Testing , 2013, Circulation.

[273]  M. Sherrid,et al.  Role of mitral valve plication in the surgical management of hypertrophic cardiomyopathy. , 2012, The Annals of thoracic surgery.

[274]  B. Gersh,et al.  Survival After Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2012, Circulation.

[275]  G. Aquaro,et al.  Progression of Myocardial Fibrosis Assessed With Cardiac Magnetic Resonance in Hypertrophic Cardiomyopathy , 2012 .

[276]  S. Colan,et al.  Outcomes of Restrictive Cardiomyopathy in Childhood and the Influence of Phenotype: A Report From the Pediatric Cardiomyopathy Registry , 2012, Circulation.

[277]  K. Gauvreau,et al.  Current Outcomes in US Children With Cardiomyopathy Listed for Heart Transplantation , 2012, Circulation. Heart failure.

[278]  Barry J Maron,et al.  Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. , 2012, Journal of the American College of Cardiology.

[279]  D. Mancini,et al.  Cardiac transplantation in patients with hypertrophic cardiomyopathy. , 2012, The American journal of cardiology.

[280]  M. Yacoub,et al.  Patterns of Disease Progression in Hypertrophic Cardiomyopathy: An Individualized Approach to Clinical Staging , 2012, Circulation. Heart failure.

[281]  M. Maron,et al.  Controversies in cardiovascular medicine Pharmacological treatment options for hypertrophic cardiomyopathy : high time for evidence , 2012 .

[282]  S. Cade,et al.  Exercise Response in Hypertrophic Cardiomyopathy: Blunted Left Ventricular Deformational and Twisting Reserve With Altered Systolic-Diastolic Coupling , 2012, Circulation. Cardiovascular imaging.

[283]  Heidi L. Rehm,et al.  Communicating new knowledge on previously reported genetic variants , 2012, Genetics in Medicine.

[284]  D. Pennell,et al.  Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy , 2014, Heart.

[285]  W. Williams,et al.  Hypertrophic cardiomyopathy in childhood: disease natural history, impact of obstruction, and its influence on survival. , 2012, The Annals of thoracic surgery.

[286]  Sondra M. Depalma,et al.  Dofetilide Reduces the Frequency of Ventricular Arrhythmias and Implantable Cardioverter Defibrillator Therapies , 2012, Journal of cardiovascular electrophysiology.

[287]  A. Capucci,et al.  Subclinical atrial fibrillation and the risk of stroke. , 2012, The New England journal of medicine.

[288]  Barry J Maron,et al.  2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Soci , 2011, Journal of the American College of Cardiology.

[289]  L. Yeates,et al.  The emerging role of the cardiac genetic counselor. , 2011, Heart rhythm.

[290]  John Spertus,et al.  AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. , 2011, Circulation.

[291]  W. Williams,et al.  Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. , 2011, Journal of the American College of Cardiology.

[292]  C. Semsarian,et al.  Natural history of genotype positive-phenotype negative patients with hypertrophic cardiomyopathy. , 2011, International journal of cardiology.

[293]  Eric A. Shry,et al.  Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. , 2011, Journal of the American College of Cardiology.

[294]  P. Elliott,et al.  Prevalence of Anderson–Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson–Fabry Disease Survey , 2011, Heart.

[295]  H. Calkins,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Heart rhythm.

[296]  David R Bassett,et al.  2011 Compendium of Physical Activities: a second update of codes and MET values. , 2011, Medicine and science in sports and exercise.

[297]  V. Hjortdal,et al.  Pregnancy with prosthetic heart valves - 30 years' nationwide experience in Denmark. , 2011, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[298]  K. Bailey,et al.  Apical hypertrophic cardiomyopathy: prevalence and correlates of apical outpouching. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[299]  Jeffrey B. Geske,et al.  Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. , 2011, JACC. Cardiovascular interventions.

[300]  S. Kushwaha,et al.  Left Ventricular Assist Device Therapy in Patients With Restrictive and Hypertrophic Cardiomyopathy , 2011, Circulation. Heart failure.

[301]  R. Hauer,et al.  Manifest disease, risk factors for sudden cardiac death, and cardiac events in a large nationwide cohort of predictively tested hypertrophic cardiomyopathy mutation carriers: determining the best cardiological screening strategy. , 2011, European heart journal.

[302]  M. Gold,et al.  Defibrillation Thresholds in Hypertrophic Cardiomyopathy , 2011, Journal of cardiovascular electrophysiology.

[303]  Vasken Dilsizian,et al.  American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: Endorsed by the American Society of Nuclear Cardiology, Society for Cardiovascular Magnetic Resonance, and Society of Cardiovascular Computed Tomograph , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[304]  Jonathan A Drezner,et al.  Incidence of Sudden Cardiac Death in National Collegiate Athletic Association Athletes , 2011, Circulation.

[305]  E. Leifer,et al.  Long-Term Follow-Up of Children and Adolescents Diagnosed with Hypertrophic Cardiomyopathy: Risk Factors for Adverse Arrhythmic Events , 2011, Pediatric Cardiology.

[306]  W. Stevenson,et al.  Long-Term Outcomes of Combined Epicardial and Endocardial Ablation of Monomorphic Ventricular Tachycardia Related to Hypertrophic Cardiomyopathy , 2011, Circulation. Arrhythmia and electrophysiology.

[307]  W. Dreyer,et al.  Restrictive Physiology is Associated With Poor Outcomes in Children With Hypertrophic Cardiomyopathy , 2011, Pediatric Cardiology.

[308]  Faha,et al.  Aha Guideline Effectiveness-based Guidelines for the Prevention of Cardiovascular Disease in Women—2011 Update a Guideline from the American Heart Association Executive Writing Committee Expert Panel Members Cvd Risk Assessment Table 1. Class Iii Interventions (not Useful/effective and May Be Harmfu , 2022 .

[309]  Perry M. Elliott,et al.  Imaging Phenotype Versus Genotype in Hypertrophic Cardiomyopathy , 2011, Circulation. Cardiovascular imaging.

[310]  Andrew S. Mugglin,et al.  Longevity of Sprint Fidelis Implantable Cardioverter-Defibrillator Leads and Risk Factors for Failure: Implications for Patient Management , 2011, Circulation.

[311]  Zahi A Fayad,et al.  2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2010, Journal of the American College of Cardiology.

[312]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[313]  A. Rynkiewicz,et al.  Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. , 2010, European heart journal.

[314]  B. Gersh,et al.  Role of family history of sudden death in risk stratification and prevention of sudden death with implantable defibrillators in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[315]  B. Maron,et al.  Timing and significance of exercise-induced left ventricular outflow tract pressure gradients in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[316]  A. Keren,et al.  Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2010, European heart journal.

[317]  B. Maron.  Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[318]  L. Køber,et al.  Comparison of Valsalva manoeuvre and exercise in echocardiographic evaluation of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. , 2010, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[319]  A. Henning,et al.  Metabolic Modulator Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy , 2010, Circulation.

[320]  R. Levine,et al.  In Vivo Measurement of Mitral Leaflet Surface Area and Subvalvular Geometry in Patients With Asymmetrical Septal Hypertrophy: Insights Into the Mechanism of Outflow Tract Obstruction , 2010, Circulation.

[321]  M. Maron,et al.  Survival After Cardiac Transplantation in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[322]  Dhanunjaya R. Lakkireddy,et al.  Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: safety and feasibility. , 2010, Heart rhythm.

[323]  W. Manning,et al.  Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[324]  T. Kubo,et al.  Clinical Features of the Dilated Phase of Hypertrophic Cardiomyopathy in Comparison With Those of Dilated Cardiomyopathy , 2010, Clinical cardiology.

[325]  Barry J Maron,et al.  Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. , 2010, The American journal of cardiology.

[326]  A. Tajik,et al.  Interactions between sleep disordered breathing and atrial fibrillation in patients with hypertrophic cardiomyopathy. , 2010, The American journal of cardiology.

[327]  A. Angelini,et al.  Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy , 2010, European heart journal.

[328]  N. Smedira,et al.  Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy. , 2010, Journal of the American College of Cardiology.

[329]  H. Schaff,et al.  Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis. , 2010, The Annals of thoracic surgery.

[330]  W. Manning,et al.  Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy , 2010, Circulation.

[331]  A. Tajik,et al.  Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[332]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[333]  A. Tajik,et al.  High prevalence of abnormal nocturnal oximetry in patients with hypertrophic cardiomyopathy. , 2009, Journal of the American College of Cardiology.

[334]  B. Gersh,et al.  Outcome of mildly symptomatic or asymptomatic obstructive hypertrophic cardiomyopathy: a long-term follow-up study. , 2009, Journal of the American College of Cardiology.

[335]  W. Manning,et al.  Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. , 2009, Journal of the American College of Cardiology.

[336]  J. Towbin,et al.  Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. , 2009, Journal of the American College of Cardiology.

[337]  Ana Morales,et al.  Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy. , 2009, Circulation. Heart failure.

[338]  C. Autore,et al.  Syncope and Risk of Sudden Death in Hypertrophic Cardiomyopathy , 2009, Circulation.

[339]  B. Maron,et al.  Successful Catheter Ablation of Hemodynamically Unstable Monomorphic Ventricular Tachycardia in a Patient with Hypertrophic Cardiomyopathy and Apical Aneurysm , 2009, Journal of cardiovascular electrophysiology.

[340]  J. Seidman,et al.  Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. , 2009, JAMA.

[341]  B. Maron,et al.  Sudden Deaths in Young Competitive Athletes: Analysis of 1866 Deaths in the United States, 1980–2006 , 2009, Circulation.

[342]  A. Capucci,et al.  Presence and Duration of Atrial Fibrillation Detected by Continuous Monitoring: Crucial Implications for the Risk of Thromboembolic Events , 2009, Journal of cardiovascular electrophysiology.

[343]  Jeroen J. Bax,et al.  Echocardiography in hypertrophic cardiomyopathy: the role of conventional and emerging technologies. , 2008, JACC. Cardiovascular imaging.

[344]  A. Kadish,et al.  Safety and efficacy of transvenous high-voltage implantable cardioverter-defibrillator leads in high-risk hypertrophic cardiomyopathy patients. , 2008, Heart rhythm.

[345]  B. Gersh,et al.  Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy , 2008, Circulation.

[346]  Eugene H Blackstone,et al.  Mitral valve abnormalities in hypertrophic cardiomyopathy: echocardiographic features and surgical outcomes. , 2008, The Annals of thoracic surgery.

[347]  P. Lambiase,et al.  Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end‐stage hypertrophic cardiomyopathy , 2008, European journal of heart failure.

[348]  D. Holmgren,et al.  Age- and gender-specific mortality rates in childhood hypertrophic cardiomyopathy. , 2008, European heart journal.

[349]  Heidi L Rehm,et al.  Shared genetic causes of cardiac hypertrophy in children and adults. , 2008, The New England journal of medicine.

[350]  S. Ommen,et al.  Utility of isoproterenol to provoke outflow tract gradients in patients with hypertrophic cardiomyopathy. , 2008, The American journal of cardiology.

[351]  H. Rakowski,et al.  Quantifying diastolic function in hypertrophic cardiomyopathy: the ongoing search for the holy grail. , 2007, Circulation.

[352]  A. Keren,et al.  Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy , 2007, Heart.

[353]  A. Tajik,et al.  Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. , 2007, European heart journal.

[354]  Mario J. Garcia,et al.  Abnormal papillary muscle morphology is independently associated with increased left ventricular outflow tract obstruction in hypertrophic cardiomyopathy , 2007, Heart.

[355]  M. Link,et al.  Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. , 2007, JAMA.

[356]  D. Fassbender,et al.  Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: managing the risk of procedure-related AV conduction disturbances. , 2007, International journal of cardiology.

[357]  S. Colan,et al.  Epidemiology and Cause-Specific Outcome of Hypertrophic Cardiomyopathy in Children: Findings From the Pediatric Cardiomyopathy Registry , 2007, Circulation.

[358]  B. Maron,et al.  Determinants for clinical diagnosis of hypertrophic cardiomyopathy. , 2006, American Journal of Cardiology.

[359]  M. Link,et al.  Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction , 2006, Circulation.

[360]  P. Elliott,et al.  Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy , 2006, Heart.

[361]  W. Manning,et al.  Prevalence, Clinical Profile, and Significance of Left Ventricular Remodeling in the End-Stage Phase of Hypertrophic Cardiomyopathy , 2006, Circulation.

[362]  W. Bamlet,et al.  Dual-Chamber Versus Single-Chamber Detection Enhancements for Implantable Defibrillator Rhythm Diagnosis: The Detect Supraventricular Tachycardia Study , 2006, Circulation.

[363]  M. Clementi,et al.  Vitamin K antagonists and pregnancy outcome , 2006, Thrombosis and Haemostasis.

[364]  E. Fain,et al.  Comparison of (cid:1) -Blockers, Amiodarone Plus (cid:1) -Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators The OPTIC Study: A Randomized Trial , 2005 .

[365]  D. Holmgren,et al.  Echocardiographic and electrocardiographic identification of those children with hypertrophic cardiomyopathy who should be considered at high-risk of dying suddenly , 2005, Cardiology in the Young.

[366]  Wojciech Zareba,et al.  Multicenter Automatic Defibrillator Implantation Trial–Cardiac Resynchronization Therapy (MADIT‐CRT): Design and Clinical Protocol , 2005, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[367]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[368]  J. Carlin,et al.  Clinical Features and Outcomes of Childhood Hypertrophic Cardiomyopathy: Results From a National Population-Based Study , 2005, Circulation.

[369]  Michael Jerosch-Herold,et al.  Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy , 2005, Circulation.

[370]  A. Tajik,et al.  Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[371]  M. Link,et al.  Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[372]  W. Mckenna,et al.  Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy , 2005, Heart.

[373]  W. Williams,et al.  Clinical and Echocardiographic Determinants of Long-Term Survival After Surgical Myectomy in Obstructive Hypertrophic Cardiomyopathy , 2005, Circulation.

[374]  B. Maron,et al.  Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[375]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[376]  C. Autore,et al.  The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. , 2005, Journal of the American College of Cardiology.

[377]  B. Maron,et al.  Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[378]  W. Williams,et al.  Hypertrophic obstructive cardiomyopathy: comparison of outcomes after myectomy or alcohol ablation adjusted by propensity score. , 2005, The Journal of thoracic and cardiovascular surgery.

[379]  Dick M. Goedhart,et al.  Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms. , 2004, Journal of the American College of Cardiology.

[380]  S. Ommen,et al.  Septal myectomy results in regression of left ventricular hypertrophy in patients with hypertrophic obstructive cardiomyopathy. , 2004, The Annals of thoracic surgery.

[381]  D. Fassbender,et al.  Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. , 2004, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.

[382]  S. Mickelsen,et al.  Doppler Evaluation of the Descending Aorta in Patients with Hypertrophic Cardiomyopathy: Potential for Assessing the Functional Significance of Outflow Tract Gradients and for Optimizing Pacemaker Function , 2004, Journal of Interventional Cardiac Electrophysiology.

[383]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[384]  D. Pennell,et al.  Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography , 2004, Heart.

[385]  J. Towbin,et al.  Characterization of Left Ventricular Diastolic Function by Tissue Doppler Imaging and Clinical Status in Children With Hypertrophic Cardiomyopathy , 2004, Circulation.

[386]  N. Smedira,et al.  Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. , 2004, The American journal of cardiology.

[387]  B. Maron,et al.  Extended septal myectomy for hypertrophic obstructive cardiomyopathy with anomalous mitral papillary muscles or chordae. , 2004, The Journal of thoracic and cardiovascular surgery.

[388]  Maurizio Schiavon,et al.  Does sports activity enhance the risk of sudden death in adolescents and young adults? , 2003, Journal of the American College of Cardiology.

[389]  A. Tajik,et al.  Adverse Prognosis of Patients With Hypertrophic Cardiomyopathy Who Have Epicardial Coronary Artery Disease , 2003, Circulation.

[390]  P. Elliott,et al.  Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. , 2003, Journal of the American College of Cardiology.

[391]  M. Quiñones,et al.  Tissue Doppler Imaging Predicts the Development of Hypertrophic Cardiomyopathy in Subjects With Subclinical Disease , 2003, Circulation.

[392]  M. S. Hamid,et al.  Pregnancy related complications in women with hypertrophic cardiomyopathy , 2003, Heart.

[393]  B. Maron,et al.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. , 2003, The New England journal of medicine.

[394]  C. Autore,et al.  Risk associated with pregnancy in hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[395]  A. Tajik,et al.  Impact of intraoperative transesophageal echocardiography in the surgical management of hypertrophic cardiomyopathy. , 2002, The American journal of cardiology.

[396]  H. Heymans,et al.  Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. , 2002, Teratology.

[397]  M. Chiariello,et al.  Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[398]  S. Solomon,et al.  Assessment of Diastolic Function With Doppler Tissue Imaging to Predict Genotype in Preclinical Hypertrophic Cardiomyopathy , 2002, Circulation.

[399]  N. Smedira,et al.  Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. , 2002, Journal of the American College of Cardiology.

[400]  B. Maron,et al.  Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[401]  A. Della Corte,et al.  Risk of Warfarin During Pregnancy With Mechanical Valve Prostheses , 2002, Obstetrics and gynecology.

[402]  B. Maron,et al.  Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy , 2001, Circulation.

[403]  B. Maron,et al.  The Electrocardiogram as a Diagnostic Tool for Hypertrophic Cardiomyopathy: Revisited , 2001, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[404]  N Freemantle,et al.  The CARE‐HF study (CArdiac REsynchronisation in Heart Failure study): rationale, design and end‐points , 2001, European journal of heart failure.

[405]  P. Elliott,et al.  Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy , 2001, The Lancet.

[406]  P. Elliott,et al.  Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. , 2000, Journal of the American College of Cardiology.

[407]  L. Faber,et al.  Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[408]  M. Sherrid,et al.  Systolic anterior motion begins at low left ventricular outflow tract velocity in obstructive hypertrophic cardiomyopathy. , 2000, Journal of the American College of Cardiology.

[409]  A. Feldman,et al.  Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investigators. , 2000, Journal of cardiac failure.

[410]  B. Maron,et al.  Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[411]  M. Link,et al.  Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2000, The New England journal of medicine.

[412]  J. Pérez,et al.  Apical hypertrophic cardiomyopathy: echocardiographic diagnosis with the use of intravenous contrast image enhancement. , 2000, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[413]  M. Decristofaro,et al.  Hypertrophic cardiomyopathy in pediatric patients: effect of verapamil on regional and global left ventricular diastolic function. , 2000, The Canadian journal of cardiology.

[414]  O. Schober,et al.  Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion. , 1999, European heart journal.

[415]  D. Nichols,et al.  Dynamic left ventricular outflow tract obstruction in acute coronary syndromes: an important cause of new systolic murmur and cardiogenic shock. , 1999, Mayo Clinic proceedings.

[416]  U. Gleichmann,et al.  Intraprocedural myocardial contrast echocardiography as a routine procedure in percutaneous transluminal septal myocardial ablation: Detection of threatening myocardial necrosis distant from the septal target area , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[417]  M. Josephson,et al.  Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). , 1999, Circulation.

[418]  B. Maron,et al.  Hypertrophic Cardiomyopathy Prognostic Value of Systemic Blood Pressure Response During Exercise in a Community-Based Patient Population With Hypertrophic Cardiomyopathy , 2016 .

[419]  M. Cotrufo,et al.  Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. , 1999, Journal of the American College of Cardiology.

[420]  P. Elliott,et al.  Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. , 1999, Journal of the American College of Cardiology.

[421]  H. Sugihara,et al.  Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hypertrophic cardiomyopathy , 1998, Annals of nuclear medicine.

[422]  B. McCrindle,et al.  Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. , 1998, Journal of the American College of Cardiology.

[423]  U. Gleichmann,et al.  Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. , 1998, Circulation.

[424]  B. McCrindle,et al.  Myocardial bridging in children with hypertrophic cardiomyopathy--a risk factor for sudden death. , 1998, The New England journal of medicine.

[425]  E. Guadagnoli,et al.  Patient participation in decision-making. , 1998, Social science & medicine.

[426]  S. Colan,et al.  Verapamil therapy in infants with hypertrophic cardiomyopathy , 1998, Cardiology in the Young.

[427]  W. Mckenna,et al.  Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. , 1997, Circulation.

[428]  W. Mckenna,et al.  Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. , 1997, European heart journal.

[429]  A. Tajik,et al.  Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. , 1997, Journal of the American College of Cardiology.

[430]  B. Maron,et al.  Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. , 1995, Journal of the American College of Cardiology.

[431]  F. Flachskampf,et al.  Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic obstructive cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. , 1995, Circulation.

[432]  J. Saul,et al.  Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome. , 1995, American heart journal.

[433]  J. Thomas,et al.  Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy. , 1995, The American journal of cardiology.

[434]  W. Chan,et al.  A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[435]  E. Rosenkranz,et al.  Benefits of intraoperative echocardiography in the surgical management of hypertrophic cardiomyopathy. , 1992, Journal of the American College of Cardiology.

[436]  K. Bailey,et al.  Dynamic Intraventricular Obstruction During Dobutamine Stress Echocardiography: A New Observation , 1992, Circulation.

[437]  W. Williams,et al.  Transesophageal Doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. , 1992, Journal of the American College of Cardiology.

[438]  H L Greene,et al.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.

[439]  M. Frenneaux,et al.  Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. , 1990, Circulation.

[440]  M. Frenneaux,et al.  Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. , 1990, Journal of the American College of Cardiology.

[441]  F. Romeo,et al.  Long‐Term prognosis in children with hypertrophic cardiomyopathy: An analysis of 37 patients aged ≤ 14 years at diagnosis , 1990, Clinical cardiology.

[442]  B. Maron,et al.  Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. , 1989, The American journal of cardiology.

[443]  R. Bonow,et al.  Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. , 1989, Circulation.

[444]  S. Kaplan,et al.  Assessing the Effects of Physician-Patient Interactions on the Outcomes of Chronic Disease , 1989, Medical care.

[445]  Sherrie H. Kaplan,et al.  Patients’ participation in medical care , 1988, Journal of General Internal Medicine.

[446]  J. Gibbs,et al.  Cardiovascular collapse after verapamil in supraventricular tachycardia. , 1987, Archives of disease in childhood.

[447]  M. Webb-Peploe,et al.  Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. , 1986, British heart journal.

[448]  W. Roberts,et al.  Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. , 1986, Journal of the American College of Cardiology.

[449]  Y. Koga,et al.  Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy. Double-blind crossover study. , 1986, Japanese heart journal.

[450]  W. Williams,et al.  Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review. , 1985, Progress in cardiovascular diseases.

[451]  J. Dussaule,et al.  Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: an echographic study. , 1985, American heart journal.

[452]  S. Kaplan,et al.  Expanding patient involvement in care. Effects on patient outcomes. , 1985, Annals of internal medicine.

[453]  R. Bonow,et al.  Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. , 1985, Circulation.

[454]  W. E. Craig,et al.  Comparison of the effects of nitroprusside and nifedipine on diastolic properties in patients with hypertrophic cardiomyopathy: altered left ventricular loading or improved muscle inactivation? , 1983, Journal of the American College of Cardiology.

[455]  W. McKenna,et al.  Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two-dimensional echocardiographic study. , 1983, Journal of the American College of Cardiology.

[456]  A. Rocchini,et al.  Hemodynamic Effects of Verapamil in Children and Adolescents with Hypertrophic Cardiomyopathy , 1983, Circulation.

[457]  J. Goodwin,et al.  Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. , 1982, British heart journal.

[458]  Michael V. Green,et al.  Effects of Verapamil on Left Ventricular Systolic Function and Diastolic Filling in Patients with Hypertrophic Cardiomyopathy , 1981, Circulation.

[459]  B. Maron,et al.  Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. , 1981, The American journal of cardiology.

[460]  B. Maron,et al.  Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. , 1979, Circulation.

[461]  E. W. Hancock,et al.  Hypertrophic subaortic stenosis. Clinical and hemodynamic effects of long-term propranolol therapy. , 1973, The American journal of cardiology.

[462]  R. Gramiak,et al.  Long-term propranolol therapy in muscular subaortic stenosis. , 1970, British heart journal.

[463]  E. Braunwald,et al.  Amelioration of Angina Pectoris in Idiopathic Hypertrophic Subaortic Stenosis with Beta‐Adrenergic Blockade , 1967, Circulation.

[464]  E. Braunwald,et al.  Hemogynamic alterations in idiopathic hypertrophic subaortic stenosis induced by sympathomimetic drugs. , 1962, The American journal of cardiology.

[465]  E. Ashley,et al.  Association of Obesity With Adverse Long-term Outcomes in Hypertrophic Cardiomyopathy. , 2020, JAMA cardiology.

[466]  S. Ommen,et al.  Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy: A propensity score–matched cohort , 2019, The Journal of thoracic and cardiovascular surgery.

[467]  C. Rooryck,et al.  Upright treadmill vs. semi-supine bicycle exercise echocardiography to provoke obstruction in symptomatic hypertrophic cardiomyopathy: a pilot study , 2018, European heart journal cardiovascular Imaging.

[468]  T. Edvardsen,et al.  Vigorous exercise in patients with hypertrophic cardiomyopathy. , 2018, International journal of cardiology.

[469]  C. Rapezzi,et al.  Efficacy of Ranolazine in Patients With Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study , 2018, Circulation. Heart failure.

[470]  D. Theuns,et al.  Incidence of Device-Detected Atrial Fibrillation and Long-Term Outcomes in Patients With Hypertrophic Cardiomyopathy. , 2017, The American journal of cardiology.

[471]  J. Healey,et al.  Wilkoff BL, et al. 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. , 2017, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[472]  B. Gersh,et al.  Cardiac resynchronization therapy in patients with end-stage hypertrophic cardiomyopathy , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[473]  J. Cigarroa,et al.  Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2016, Journal of the American College of Cardiology.

[474]  H. Calkins,et al.  2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2016, Journal of the American College of Cardiology.

[475]  M. Hannan,et al.  The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. , 2016, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[476]  L. Eckardt,et al.  Long-term follow-up of subcutaneous ICD systems in patients with hypertrophic cardiomyopathy: a single-center experience , 2015, Clinical Research in Cardiology.

[477]  DanielePasqualucci,et al.  Clinical Spectrum, Therapeutic Options, and Outcome of Advanced Heart Failure in Hypertrophic Cardiomyopathy , 2015 .

[478]  L. Shaw,et al.  ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[479]  N. Smedira,et al.  Exercise echocardiography in asymptomatic HCM: exercise capacity, and not LV outflow tract gradient predicts long-term outcomes. , 2014, JACC. Cardiovascular imaging.

[480]  Hugh Calkins,et al.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. , 2014, Journal of the American College of Cardiology.

[481]  F. Hu,et al.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. , 2014, Journal of the American College of Cardiology.

[482]  Biykem Bozkurt,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[483]  B. Gersh,et al.  Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[484]  C. Vosa,et al.  Asymmetric septal hypertrophy in patients with severe aortic stenosis: the usefulness of associated septal myectomy. , 2013, The Journal of thoracic and cardiovascular surgery.

[485]  Christophe Leclercq,et al.  2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[486]  P. Pieper,et al.  Pregnancy in women with hypertrophic cardiomyopathy , 2012, Netherlands Heart Journal.

[487]  M. Sherrid,et al.  Standing and exercise Doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity. , 2011, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[488]  N. Smedira,et al.  Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. , 2008, The Annals of thoracic surgery.

[489]  Daniel W. Jones,et al.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. , 2004, Hypertension.

[490]  G. Borg.  Psychophysical bases of perceived exertion. , 1982, Medicine and science in sports and exercise.